TRN 110
Alternative Names: TRN-110Latest Information Update: 22 Jan 2023
At a glance
- Originator Tris Pharma
- Class Neuropsychotherapeutics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Attention-deficit hyperactivity disorder
Most Recent Events
- 12 Dec 2022 TRN 110 is still in preregistration phase for Attention deficit hyperactivity disorder in USA (Tris pharma pipeline; December 2022)
- 01 Dec 2022 TRN 110 licensed to Pediatrix Therapeutics in China
- 26 Aug 2020 Preregistration for Attention-deficit hyperactivity disorder (In adolescents, In children, In adults) in USA (PO) before August 2020 (Tris Pharma pipeline, August 2020)